Affimed (Nasdaq:AFMD) - Cotización, noticias y análisis

Resumen de acción AFMD

Affimed N.V., empresa biofarmacéutica en fase clínica, se centra en el descubrimiento y desarrollo de inmunoterapias contra el cáncer en Estados Unidos y Alemania.

Acerca de la empresa

AFMD fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 50.37%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Tiene menos de 1 año de cash runway

No tiene una capitalización de mercado significativa ($74M)

Volatilidad del precio de la acción en los últimos 3 meses

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de Affimed N.V.

HOOKIPA Pharma

NasdaqCM:HOOK

US$79.2m

Elutia

NasdaqCM:ELUT

US$71.1m

Precision BioSciences

NasdaqCM:DTIL

US$73.1m

Serina Therapeutics

NYSEAM:SER

US$79.0m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Affimed
Historical stock prices
Current Share Price	US$5.23
52 Week High	US$11.10
52 Week Low	US$2.24
Beta	2.09
1 Month Change	-14.26%
3 Month Change	-4.47%
1 Year Change	-42.90%
3 Year Change	-94.10%
5 Year Change	-85.01%
Change since IPO	-90.82%

Noticias y actualizaciones recientes

Recent updates

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

Aug 15

Need To Know: Analysts Just Made A Substantial Cut To Their Affimed N.V. (NASDAQ:AFMD) Estimates

Apr 20

Announcing: Affimed (NASDAQ:AFMD) Stock Increased An Energizing 177% In The Last Three Years

Feb 15

Affimed and Roche collaborate to study AFM24 in solid tumors

Feb 03

Affimed N.V. initiates equity offering

Jan 12

Affimed inks €25M debt financing deal with Silicon Valley Bank

Jan 11

Affimed updates on product pipeline and cash balances

Jan 07

Affimed (NASDAQ:AFMD) Has Debt But No Earnings; Should You Worry?

Dec 25

What Did Affimed's (NASDAQ:AFMD) CEO Take Home Last Year?

Dec 04

Rentabilidad de los accionistas

	AFMD	US Biotechs	Mercado US
7D	-1.3%	1.3%	3.3%
1Y	-42.9%	3.0%	25.0%

Rentabilidad vs. Industria: AFMD obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del -2.3%.

Rentabilidad vs. Mercado: AFMD obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is AFMD's price volatile compared to industry and market?
AFMD volatility
AFMD Average Weekly Movement	12.6%
Biotechs Industry Average Movement	11.4%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de AFMD ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de AFMD(12%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2000	76	Andreas Harstrick	www.affimed.com

Affimed N.V., empresa biofarmacéutica en fase clínica, se dedica al descubrimiento y desarrollo de inmunoterapias contra el cáncer en Estados Unidos y Alemania. Entre los principales productos candidatos de la empresa figuran el AFM13, que ha completado el ensayo clínico de fase 2 para el linfoma CD30-positivo, el ensayo clínico de fase Ib para el linfoma de Hodgkin y el estudio clínico de fase IIb para el linfoma periférico de células T; AFM24, un receptor del factor de crecimiento epidérmico tetravalente y biespecífico y un captador de células innatas unido a CD16A, que se halla en fase IIa de ensayo clínico para el tratamiento de cánceres avanzados; y AFM28, un captador de células innatas (ICE), que está en desarrollo preclínico para el tratamiento del mieloide agudo. Desarrolla AFM32, un candidato a ICE que está en desarrollo preclínico para el tratamiento de tumores sólidos.

Resumen de fundamentos de Affimed N.V.

¿Cómo se comparan los beneficios e ingresos de Affimed con su capitalización de mercado?
Estadísticas fundamentales de AFMD
Capitalización bursátil	US$79.64m
Beneficios(TTM)	-US$113.83m
Ingresos (TTM)	US$14.95m

5.3x

Ratio precio-ventas (PS)

-0.7x

Ratio precio-beneficio (PE)

¿Está AFMD sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de AFMD
Ingresos	€13.91m
Coste de los ingresos	€0
Beneficio bruto	€13.91m
Otros gastos	€119.85m
Beneficios	-€105.94m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-6.96
Margen bruto	100.00%
Margen de beneficio neto	-761.38%
Ratio deuda/patrimonio	21.0%

¿Cómo se ha desempeñado AFMD a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción AFMD

Recompensas

Análisis de riesgos

Competidores de Affimed N.V.

NasdaqCM:HOOK

US$79.2m

NasdaqCM:ELUT

US$71.1m

NasdaqCM:DTIL

US$73.1m

NYSEAM:SER

US$79.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Affimed N.V. to Report Fiscal Year 2023 Results on Mar 28, 2024

Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer

Affimed N.V. Announces CEO Changes

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors (Cpis)

Affimed N.V. Announces Executive Changes

Affimed N.V. to Report Q3, 2023 Results on Nov 14, 2023

Recent updates

Affimed N.V. to Report Fiscal Year 2023 Results on Mar 28, 2024

Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer

Affimed N.V. Announces CEO Changes

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors (Cpis)

Affimed N.V. Announces Executive Changes

Affimed N.V. to Report Q3, 2023 Results on Nov 14, 2023

Affimed N.V. Presents Preclinical Data Showing That Addition of an Innate Cell Engager to Nk and Car-Nk Cells

Affimed N.V. Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 14%

Affimed N.V. to Report Q2, 2023 Results on Aug 10, 2023

Affimed N.V.(NasdaqGM:AFMD) dropped from Russell 2000 Dynamic Index

New minor risk - Market cap size

Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board

Consensus revenue estimates decrease by 22%

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Affimed N.V., Annual General Meeting, Jun 21, 2023

Affimed N.V. to Report Q1, 2023 Results on May 23, 2023

Affimed N.V. Announces Abstracts at Annual Meeting of European Hematology Association

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Affimed N.V. Provides Regulatory Update for AFM13

Affimed N.V. Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

Affimed N.V. Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells

Consensus revenue estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. to Report Q3, 2022 Results on Nov 15, 2022

Affimed N.V. Announces Presentation of Phase 1/2 Data from Afm13 in Combination with Allogeneic NK Cells and Preclinical Afm28 Data At Ash 2022 Annual Meeting

Affimed downgraded to hold at Stifel as pipeline lacks development clarity

Health Check: How Prudently Does Affimed (NASDAQ:AFMD) Use Debt?

Now 26% undervalued after recent price drop

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed Q2 2022 Earnings Preview

Affimed N.V. to Report Q2, 2022 Results on Aug 11, 2022

Affimed N.V. Establishes Scientific Advisory Board

Affimed: Preparing For Key Inflection Points

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed N.V. Announces Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies At the Annual Meeting of the American Society of Clinical Oncology

Affimed N.V. to Report Q1, 2022 Results on Jun 01, 2022

Affimed N.V. Presents Data on Innate Cell Engagers Afm24 and Afm28 at 19th Meeting of the Society for Natural Immunity

Affimed N.V. Announces Data from the Dose Escalation Phase of the Phase 1/2A Study with the company’s Innate Cell Engager

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

Affimed N.V. Presents Findings from the Dose-Escalation Phase of the First-In-Human Study of AFM24 in Patients with EGFR-Positive Solid Tumors

Affimed Stock: 3 Points For The Bulls

Consensus revenue estimates fall by 23%

Affimed N.V. (NASDAQ:AFMD) Analysts Just Cut Their EPS Forecasts Substantially

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers After Freezing & Thawing

Affimed N.V. Announces Completion of Enrollment in Redirect, the Registration-Directed Study of Afm13 in PTCL

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed N.V. to Discuss Treatment of Cd30-Positive Lymphoma Patients with Cord Blood-Derived Natural Killer Cells Pre-Complexed with Innate Cell Engager AFM13